Q-omics provides the consensus-scored GUSBP7 profile across patient tissues and cancer cell-line models. GUSBP7 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, GUSBP7 is differentially expressed in 6, with the highest sampling consensus in KIRC. Additionally, GUSBP7 RNA expression shows 8,073 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight MESO, KIRC, and TGCT as cancer lineages where GUSBP7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GUSBP7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GUSBP7 survival associations across molecular data types. GUSBP7 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GUSBP7 RNA expression–survival associations across cancer types. High GUSBP7 expression shows unfavorable associations in MESO, THCA, CESC and GBM, but favorable associations in UCS and LGG. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify MESO as the clearest survival context for GUSBP7 RNA expression.
This table summarizes GUSBP7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for GUSBP7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GUSBP7 shows lower tumor expression in THCA and STAD and higher tumor expression in KIRC, HNSC, COAD and LUSC. The KIRC box plot shows higher GUSBP7 RNA expression in tumor versus normal tissue (log2 FC = +0.036, t-test p < 0.001).
This table shows molecular features associated with GUSBP7 in patient tissues and cancer cell lines. In patient samples, GUSBP7 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
